Get Back to Work limited offer: $475 (Standard $525). Use code SAVE50. Start Now
Call 888-895-8179

DOT Drug Testing Process

The three-stage path a urine drug test follows: collection, laboratory analysis, and MRO review. ← Testing Mechanics

Short Answer

A DOT drug test moves through three stages, each handled by a different service agent. First, a collector obtains a urine specimen at a collection site and documents the collection on the Federal Custody and Control Form, commonly called the CCF. Second, the specimen moves through a documented chain of custody to a laboratory certified by the Department of Health and Human Services (HHS), where it is analyzed. Third, if the laboratory reports anything other than a routine negative, a Medical Review Officer (MRO), a licensed physician, reviews the result and any medical explanation before it becomes final. A drug test result is not considered "verified" until the MRO completes that review.

Step One: Collection

The collector is the person who instructs and assists the employee at the collection site and completes the CCF. The collector's job is procedural rather than medical: following the required steps in order, labeling the specimen correctly, and documenting each part of the process.

The specimen is normally divided into two portions at the time of collection. The primary specimen, sometimes called the "A" bottle, is tested first. The split specimen, or "B" bottle, is retained and can be tested separately if the employee later requests it, typically after a verified positive, adulterated, or substituted result on the primary specimen.

Every step, from the moment the collector receives the specimen until it is eventually destroyed, is documented through the chain of custody, the paperwork trail on the CCF showing who handled the specimen and when.

Step Two: Laboratory Analysis

The primary specimen is shipped to a laboratory certified under HHS Mandatory Guidelines. DOT rules require the use of an HHS-certified laboratory for regulated drug testing. The laboratory tests for the drug classes covered under 49 CFR Part 40: marijuana, cocaine, amphetamines, phencyclidine (PCP), and opioids.

The laboratory reports one of several outcomes to the MRO. A negative result means no drug was detected, or the amount detected fell below the cutoff, on a specimen that tested as valid human urine. A non-negative specimen is one that comes back adulterated, substituted, positive, or invalid. Any non-negative result triggers MRO review before anything reaches the employer.

Step Three: MRO Review

The MRO is a licensed physician responsible for receiving laboratory results and evaluating medical explanations for certain outcomes. The MRO does not repeat the laboratory's chemistry. Instead, the MRO reviews the paperwork, contacts the employee when required, and considers whether a legitimate medical explanation accounts for a non-negative finding, for example a lawfully prescribed medication that could explain an opioid finding.

Once the MRO completes this review, the result becomes a verified test: a laboratory result that has undergone MRO review and reached a final determination. Only a verified positive result, or a verified refusal, adulterated, or substituted finding, triggers the consequences that follow a DOT drug violation.

When Problems Interrupt the Process

Not every test proceeds cleanly from collection to a verified result. 49 CFR Part 40, Subpart I, addresses several categories of problems. An employee can be treated as having refused the test for reasons described at 49 CFR § 40.191, including failing to provide a sufficient specimen without an adequate medical explanation. A specimen that is insufficient in volume triggers the procedure at 49 CFR § 40.193. Certain flaws always cancel a test under 49 CFR § 40.201, while other, more minor flaws cancel a test only if they go uncorrected, under 49 CFR § 40.203. A cancelled test counts as neither positive nor negative.

Applicable Regulations

  • 49 CFR § 40.3 defines the collector, MRO, chain of custody, primary specimen, split specimen, and other terms used throughout the testing process.
  • 49 CFR §§ 40.191, 40.193, 40.201, and 40.203 (Subpart I) govern refusals, insufficient specimens, and cancelled tests.

Applicable Guidance

SAMHSA, the Substance Abuse and Mental Health Services Administration, certifies the laboratories used for DOT-regulated drug testing under HHS Mandatory Guidelines. This certification structure operates alongside Part 40 and is referenced by it, rather than being written into Part 40 itself.

Professional Observation

In my experience, many employees assume the laboratory has the final word on a drug test result. It doesn't. The laboratory reports a scientific finding, but the MRO decides what that finding means for the employee's DOT status. Understanding that distinction early helps employees know who to actually talk to, the MRO, if there is a legitimate medical explanation to raise.

Common Misconceptions

Misconception

A positive laboratory result and a positive drug test are the same thing.

Reality

A laboratory result becomes a verified result only after MRO review. Until then, it is a laboratory finding, not a final DOT drug test outcome.

Why the Confusion Occurs

Casual references to "failing a drug test" often describe the moment a lab reports a non-negative finding, before MRO review has even started.

Frequently Asked Questions

Does the employee ever speak with the laboratory directly?

No. The laboratory reports results to the MRO, not to the employee or the employer. Any conversation about a medical explanation for a non-negative result happens with the MRO.

What happens to the split specimen if the primary result is negative?

If the primary specimen is negative, the split specimen is generally not tested and is eventually discarded according to laboratory retention practices.

Related Articles

Primary Authorities/Sources

Have Questions About a Specific Test?

If you have a question about where a test currently stands in this process, start by confirming the details with your employer's DER or the reviewing MRO.

Schedule a Consultation

Reviewed by: Perret deLapouyade, CEAP, SAP
Reviewed date: July 12, 2026
Updated date: July 12, 2026
BOK ID: BOK-0026